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SUMMARY

The Hedgehog (Hh) pathway regulates cell differentiation and proliferation during development by
controlling the Gli transcription factors. Cell fate decisions and progression toward organ and tissue
maturity must be coordinated, and how an energy
sensor regulates the Hh pathway is not clear. AMPactivated protein kinase (AMPK) is an important
sensor of energy stores and controls protein synthesis and other energy-intensive processes. AMPK is
directly responsive to intracellular AMP levels, inhibiting a wide range of cell activities if ATP is low and
AMP is high. Thus, AMPK can affect development
by inﬂuencing protein synthesis and other processes
needed for growth and differentiation. Activation of
AMPK reduces GLI1 protein levels and stability,
thus blocking Sonic-hedgehog-induced transcriptional activity. AMPK phosphorylates GLI1 at serines
102 and 408 and threonine 1074. Mutation of these
three sites into alanine prevents phosphorylation by
AMPK. This leads to increased GLI1 protein stability,
transcriptional activity, and oncogenic potency.
INTRODUCTION
Regulation of energy production and storage is necessary for
living organisms, especially during stages of development that
involve substantial growth. Otherwise embryos may invest
precious energy in starting organogenesis that cannot be
completed. The problem is exempliﬁed by the crucial function
of mitochondria, which are the major source of ATP during
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human pre-implantation development (Wilding et al., 2009).
Therefore, developmental control systems that guide the growth
of organs and tissues must be coordinated with energy supply.
The Hedgehog (Hh) pathway is essential for the development
of most organs and tissues. Loss of control of the pathway is
oncogenic in tissues where a normal role of the Hh signal is to
promote growth. Mutations that deregulate Hh signaling are
associated with sporadic and familial skin cancer (basal cell
carcinoma) and brain tumors (medulloblastoma). For example,
Gorlin syndrome is due to loss-of-function mutations in the
PTCH gene, which encodes the receptor protein Patched1
(Ptch) that binds Hh ligand. Normally Ptch protein restrains Hh
transduction, and therefore growth of the skin and cerebellum,
until it is inactivated by the Hh ligand; but, the tumor cells sense
the loss of Ptch function and divide without the need for Hh signals. Given the ﬁne line between mitogenesis and oncogenesis,
appropriate regulation of developmental pathways is critical.
Hh signaling controls transcription of target genes by
regulating activities of the three Glioma-associated oncogene
(Gli1–3) transcription factors. When Hh ligand binds to the Ptch
receptor, a 12-pass transmembrane protein, Ptch no longer inhibits the 7-transmembrane domain transducer Smoothened
(Smo). In cells not exposed to Hh ligand, Ptch is resident in the
plasma membrane overlying primary cilia (Rohatgi et al., 2007);
Ptch moves into the cell and is degraded upon binding Hh.
Activated Smo then accumulates in primary cilia, which are
non-motile solitary appendages on many cell types and serve
as transduction centers for Hh signals (Rohatgi et al., 2007). Activation of Smo antagonizes Sufu, a Gli1 negative regulator, to
promote nuclear translocation of active Gli proteins and induction of genes that control cell proliferation or differentiation during development.
Embryos devote speciﬁc regulatory systems to conserving or
increasing the energy supply during times of need. One crucial
Cell Reports 12, 599–609, July 28, 2015 ª2015 The Authors 599
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energy-sensing molecule is AMP-activated protein kinase
(AMPK). AMPK monitors cellular energy status by responding
to AMP/ATP ratios, as well as AMP and ATP concentrations
(Scott et al., 2009; Steinberg and Kemp, 2009). The levels of
AMP and ATP reﬂect environmental nutrient supply and uptake. High AMP activates AMPK, which then inhibits energyconsuming processes such as protein synthesis, and boosts
energy production by increasing glucose uptake and glycolysis
(Hardie et al., 2012).
AMPK is a heterotrimer consisting of a, b, and g subunits.
AMPK is activated approximately 1,000-fold by phosphorylation
of a conserved threonine (Thr172) in the activation loop of the KD
by upstream protein kinases, such as serine/threonine kinase
11 (STK11, also known as Liver Kinase B1 [LKB1]) (Jishage
et al., 2002). When AMP or ADP concentrations are high, their
increased binding to the g subunit causes a conformational
change that promotes phosphorylation of Thr172 by LKB1 and
inhibits dephosphorylation (Xiao et al., 2011). Genetic experiments show that zebraﬁsh embryos do not require LKB1 if
energy is abundant; but, in conditions of energy stress, LKB1
is essential for life (van der Velden et al., 2011). The kinase activity of mammalian phosphorylated AMPK can be enhanced 2- to
5-fold by the binding of AMP to its g subunit (Sanders et al., 2007;
Suter et al., 2006). ATP is an antagonist of AMPK activation,
acting by binding to the g subunit and competing with AMP or
ADP binding (Hardie et al., 2012; Xiao et al., 2007).
Development cannot proceed if energy stores are inadequate.
Slowing or postponing developmental steps may save the life of
a growing animal. Hh signaling recently has been shown to
trigger rapid glycolysis in adipocytes by modifying Smo activity,
Ca2+ levels, and AMPK activity (Teperino et al., 2012). Thus, the
Hh developmental pathway alters production of ATP. We have
been investigating the complementary possibility that transduction through the Hh pathway is modulated by energy stores.
When energy is scarce and cell division or cell differentiation
should be slowed to conserve remaining stores, activated
AMPK may indirectly affect developmental pathways like Hh
by reducing protein synthesis or other basic gene expression
functions. A second possibility is that a more direct regulatory
connection links energy sensing with developmental regulators.
We have investigated this second possibility using cultured cells
that respond to Hh signaling proteins.
RESULTS
Control of Gli1 Protein Level and Stability by AMPK
To investigate whether AMPK regulates the Hh pathway, we
used the NIH 3T3 cell line, a well-known Hh-responsive cell
line. Cells were treated with the AMPK activator two-deoxyglucose (2DG), a glucose analog that blocks ATP production by inhibiting glycolysis and thereby induces AMPK activation (Wick
et al., 1957). Activation of AMPK reduced Gli1 protein levels progressively over time (Figure 1A). As NIH 3T3 cells were treated for
increasing numbers of hours with 2DG, the amount of activated
AMPK (p-AMPK) increased. The amount of a direct AMPK
substrate that is often used to measure AMPK activity (Henin
et al., 1995), phospho-Acetyl-CoA Carboxylase (p-ACC), also
increased for at least 4 hr. In addition to 2DG, similar effects
600 Cell Reports 12, 599–609, July 28, 2015 ª2015 The Authors

were observed when two other AMPK activators (A769662 and
AICAR) were applied to NIH 3T3 and pZp53Med1 (Med1) medulloblastoma cells (Figure 1B). In addition, protein levels of Gli2 and
Gli3 (FL and R) did not change while AMPK was activated (Figure S1A). AMPK knockout MEF cells had increasing (1.71-fold)
Gli1 protein compared to wild-type (WT) MEF, and the amount
of Gli1 protein was low in AMPK+/+ cells in the presence of
2DG and did not change in the AMPK / cells (Figure 1C). Therefore, the low level of Gli1 protein caused by 2DG administration
was due to AMPK-dependent action.
Knocking down Lkb1 dysregulates the Hh pathway by
affecting Gli3 (Jacob et al., 2011). We found that two different
Lkb1 small hairpin RNAs (shRNAs) reduced the level of Lkb1 protein by half in Med1 cells, while the level of Gli1 protein was not
affected (Figure S1B). In Lkb1 / myoblast cells, both Gli1 protein and mRNA levels were not much different in comparison
with Lkb1+/+ cells (Figures S1C and S1D). When Lkb1+/+ and
Lkb1 / cells were treated with AICAR, Gli1 protein level was
reduced in both (Figure S1C). We conclude that Lkb1 is not
involved in the AMPK-mediated reduction of the Gli1 protein
levels. HEK293 cells were transfected with a kinase-dead
AMPK mutant (Banko et al., 2011) that is unable to phosphorylate proteins. The result was an increase in the Gli1 protein level
compared to cells transfected with WT AMPK (Figure 1D).
Gli1 is transcriptionally activated by Shh. Activating AMPK
reduced Gli1 protein levels in NIH 3T3 cells despite stimulation
with Shh ligand (Figure 1E). Co-treatment of the cells with 2DG
and Shh increased the amount of activated AMPK measured
as p-AMPK and its target p-ACC, and reduced the amount of
Gli1 protein compared to cells treated with Shh alone. Med1
cells, which have constitutively active Hh target gene expression
(Berman et al., 2002), also had reduced Gli1 protein levels in the
presence of 2DG (Figure 1F). The reduction of Gli1 protein may
have been due to protein degradation. Co-treatment with 2DG
and proteasome inhibitor (MG132) restored the higher amount
of Gli1 protein (Figure S1E). This indicates that, even upon stimulation by Shh, which increases the amount of Gli1 protein
because Gli1 is a transcriptional target, activated AMPK is able
to reduce Gli1 protein levels.
The reduction of the Gli1 protein level by activated AMPK
could be due to an effect on Gli1 transcription, translation, or
post-translational stability. We ﬁnd that Gli1 protein stability is
altered by the activity state of AMPK. We used cycloheximide
(CHX) to block translation of new protein and monitored the stability of pre-existing Gli1 protein. When AMPK was functional
(Figure 1G, left), the amount of Gli1 protein decreased with a
half-life of 4 hr. In cells lacking AMPK (Figure 1G, right), Gli1 protein remained stable with a half-life of at least 8 hr. Gli1 instability
was accelerated in 2DG and CHX co-treated AMPK+/+ cells (Figure 1H), but was not affected in AMPK / cells (Figure 1H). The
protein stabilities of Gli2 and Gli3 were not affected in the 2DG
and CHX co-treated Med1 cells (Figure S1F). In this experiment
AMPK could not have been affecting synthesis of Gli1, which
was prevented, but instead affected Gli1 protein stability.
AMPK Reduces Gli1 Transcriptional Activity
We tested whether AMPK activation affects Gli1 mRNA levels in
addition to reducing Gli1 protein stability. In AMPK / cells, Gli1
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and Ptch1 mRNA were elevated about 2-fold compared to
AMPK+/+, and, consistently, mRNA from the two target genes
was higher in DN-AMPK-transfected cells compared to WTAMPK-transfected cells (Figures S2A and S2B). In NIH 3T3 cells,
treatment with 2DG, A769662, and AICAR led to a time-dependent reduction in the level of mRNA from Gli1 and from another
target, Ptch1 (Figures 2A–2C). During the 4-hr time period of
examination in these experiments, the activation of AMPK by
2DG, A769662, or AICAR shut down translation and transcription, but the effect was not a general effect on mRNA levels
because the control mRNA measured (Gapdh) did not change
in amount (Figures 2A–2C). Instead, the reduced Gli1 protein,
due to its instability and lowered synthesis, caused lower levels
of Gli1 and Ptch1 transcripts. In AMPK / cells, Gli1 mRNA remained at the same level in the presence of AICAR (Figure 2D).
This result is consistent with the results shown in Figure S2A.
Gli1 protein level was not affected in the presence of 2DG in
AMPK / cells. In keeping with this, the addition of AMPK activa-

-

tors together with Shh lowered Gli1 and Ptch1 mRNA levels
compared to induction of those targets with Shh alone (Figures
2E and S2C).
In addition to our in vitro studies with cell lines, we examined
whether AMPK controls gli1 mRNA in an in vivo context. In
zebraﬁsh embryos, treatment with 2DG led to AMPK activation
and inhibition of the activity of its downstream substrate
(p-ACC) (Figure S2D). Measuring gli1 and ptch1 mRNA levels,
we found a reduction in expression levels of these genes in the
2DG-treated group compared with the untreated group (Figure S2E). Injection of ampk morpholino (MO) into zebraﬁsh
embryos led to a reduction of ampk mRNA level in comparison
with the control MO (5 bp mismatches of the ampk MO) (Li
et al., 2013) and 2-fold elevation of gli1 and ptch1 mRNA levels
compared to the control group (Figure S2F).
AMPK may be acting on Gli1 mRNA levels directly or indirectly,
so we used a reporter gene assay to look at direct target gene
regulation. We used a synthetic target gene consisting of eight
Cell Reports 12, 599–609, July 28, 2015 ª2015 The Authors 601
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Figure 2. AMPK Inhibits GLI1 Transcriptional Activity
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(A–C) NIH 3T3 cells were treated with (A) 25 mM
2DG, (B) 150 mM A769662, and (C) 0.75 mM AICAR
for the indicated hours, and the amount of Gli1 or
Ptch1 mRNA was analyzed by RT-qPCR with
Gapdh mRNA as the internal control and normalized to the time zero Gli1 and Ptch1 mRNA levels.
The control is provided by time zero, when no
chemicals were applied, so the bars indicate Gli1
and Ptch1 mRNA levels relative to those of Gapdh
and normalized to levels at time zero.
(D) AMPK+/+ and AMPK / MEFs were treated with
0.75 mM AICAR for the indicated hours and
analyzed by RT-qPCR as shown as (A).
(E) NIH 3T3 cells were SS in DMEM (0.5% BCS)
overnight, stimulated with Shh with or without
25 mM 2DG for 6 hr, and the amount of Gli1 or
Ptch1 RNA was analyzed by RT-qPCR and
normalized to Gli1 and Ptch1 mRNA levels in SS
cells. Three replicate experiments were done
with SDs.
(F) HEK293 cells were co-transfected with Gli1RE-Luciferase reporter, GLI1, and constitutively
active AMPK (CA-AMPK), and maintained for
36 hr. Cell lysates were analyzed using a luciferase
assay to measure reporter-gene transcriptional
regulation by GLI1. Representative results from
three experiments (n = 3) conducted in duplicate
are shown with SDs.

+

CA-AMPK

Gli-binding sites joined to a luciferase reporter (Sasaki et al.,
1997; Figure 2F). Transfection of HEK293 cells with the reporter
transgene, and another plasmid that encoded constitutively
active AMPK, suppressed induction by Gli1. As we show in the
following experiments, target gene expression is lower because
activated AMPK phosphorylates and destabilizes Gli1 protein,
not because AMPK directly reduces Gli1 mRNA.
Direct Regulation of Gli1 Protein Stability by AMPK
We next examined the mechanism of the inﬂuence of AMPK on
Gli1 protein stability. To investigate whether AMPK alters Gli1
phosphorylation, we used a chemical genetic approach. The
method allows speciﬁc labeling of direct substrates of a protein
kinase in living cells, thus distinguishing direct from indirect inﬂuences of a kinase (Alaimo et al., 2001). ATP-binding pockets of
protein kinases contain a conserved gatekeeper residue that,
during the reaction, is in close contact with the N6 position of
the adenine ring of ATP. Substituting a smaller amino acid for
this gatekeeper residue enables the mutant protein kinase,
which is termed analog speciﬁc (AS), to use ATP analogs containing bulky groups at the N6 position (Allen et al., 2007). In
contrast, bulky ATP analogs are poor substrates for WT kinases
602 Cell Reports 12, 599–609, July 28, 2015 ª2015 The Authors

due to steric hindrance by the gatekeeper
residue. N6-modiﬁed ATPgS nucleotides
are accepted by the AS kinase, and
the transferred thiophosphate can be
+
+
alkylated and recognized by a speciﬁc
monoclonal antibody, thioP antibody
(Allen et al., 2005, 2007). The power of
the approach is exempliﬁed by an AS version of AMPKa2
(AS-AMPKa2) that was used to identify AMPK substrates in
HEK293T cells (Banko et al., 2011).
Using the same protocol, we co-transfected genes encoding
HA-tagged WT or AS-AMPKa2 with the two other AMPK subunits b1 and g1, as well as with genes for Flag-tagged GLI1
and FOXO3a into HEK293 cells. Flag antibody was used to
immunoprecipitate GLI1 and FOXO3a proteins. FOXO3 is the
AMPK target that served as a positive control. The precipitate
was analyzed by immunoblotting with thioP antibody to detect
phosphorylated GLI1 and FOXO3a. In AS-AMPKa2-transfected
cells treated with 2DG, we found increased phosphorylated
GLI1 compared with WT-AMPKa2-transfected cells, as well as
increased phosphorylated FOXO3a (Figure 3A).
In the next experiment, we used AMPK phospho-substratespeciﬁc antibody (p-Sub/AMPK) (Gwinn et al., 2008), and we
found that Gli1 was phosphorylated in AMPK-transfected cells.
HEK293 cells were transfected with Flag-tagged Gli1 alone ( )
or with AMPK as well (+). Flag-tagged GLI1 was immunoprecipitated with anti-Flag antibodies and separated on a protein gel.
The blot was probed with antibodies against AMPK phosphosubstrate (p-Sub/AMPK), Flag, AMPK, and tubulin (Figure 3B).

.

The results show that GLI1-Flag was at comparable levels in
both extracts, while AMPK was detected only in AMPK-transfected cells; a prominent band was observed with the p-Sub
antibody only in cells that had been transfected with AMPK.
We generated MEFs with stable GLI1-Flag expression in
AMPK+/+ and AMPK / cells to verify that phosphorylation of
GLI1 is AMPK dependent. AMPK was activated using 2DG and
AICAR, and Flag-tagged GLI1 was immunoprecipitated with
anti-Flag from AMPK+/+ and AMPK / cell lines. In the immunoprecipitates, a prominent band was observed with the p-Sub/
AMPK antibody in AMPK+/+ MEFs, but not in AMPK / MEFs
(Figure 3C). These results conﬁrm the identity of the AMPKphosphorylated protein as GLI1.
To discover which GLI1 amino acids were phosphorylated by
AMPK, HEK293 cells were co-transfected with either WT-AMPK
or DN-AMPK, and GLI1. GLI1 was puriﬁed from cell extracts using immunoprecipitation with Flag antibody, and further puriﬁed
by isolating the GLI1 protein from an SDS gel. Mass spectrometry showed that GLI1 was phosphorylated at sites S102,
S408, and T1074 (Figures 3D and S3). The same result was obtained in cells transfected with WT-AMPK, but not if the cells
were transfected with DN-AMPK. Fourteen potential phosphopeptides were observed after two independent WT-AMPK transfections (Figures S3B–S3D, yellow). Three of these peptides
were not phosphorylated in DN-AMPK-transfected cells (Figures
S3B–S3D, red circles). In parallel, GLI1 was puriﬁed from stable
GLI1-Flag expression AMPK+/+ MEFs treated with and without
2DG to modulate endogenous AMPK activity. The same result
was found that GLI1 was phosphorylated at sites S102, S408,
and T1074 in 2DG-treated AMPK+/+ MEFs (Figure S3E). Without
2DG, phosphorylations of S102 and S408 were not detected on
GLI1 (Figure S3F). The results indicate that the phosphorylation
changes of these sites are in response to metabolic stress in
cells.
The sequence for S408 matches the AMPK consensus
LRRVXS/TXXXL, but is not conserved in mouse and zebraﬁsh.
S102 and T1074 are conserved in the GLI1 proteins of humans,
mice, and zebraﬁsh (Figure 3E), but do not perfectly match the
optimal AMPK consensus motif (Table S1).
The three AMPK-phosphorylated amino acids in GLI1 were
changed to alanines by mutating the Gli1 gene, i.e., S102A,
S408A, and T1074A. This protein, GLI13A, should be immune
to AMPK phosphorylation. HEK293 cells were co-transfected
with DNA that encoded either WT-AMPKa2 or AS-AMPKa2,
and a construct encoding GLI1WT or GLI13A tagged with a Flag
epitope. AS-AMPKa2 no longer phosphorylated the FlagGLI13A protein (Figure 3F), with the signal dropping to the background levels (0.8 arbitrary units) seen in cells transfected with
WT GLI1 (2.69 arbitrary units).
An anti-phospho-GLI1 T1074 antibody was prepared that is
highly speciﬁc. Immunoprecipitated WT GLI1-Flag was stained
with the p-GLI11074 antibody (Figure 3G, top middle lane), while
the GLI13A mutant (Figure 3G, top right lane) was much less so.
The activation of AMPK was demonstrated here by the phosphoAMPK antibody and by the appearance of p-ACC. In this experiment, 2DG was administered for only 30 min, sufﬁcient to
activate AMPK, but not long enough to cause loss of GLI1 protein (Figures 1A and 1F). 2DG was necessary for substantial

labeling of the WT protein (Figure 3G, top middle lane compared
to top left lane). The 2DG-driven phosphorylation of GLI1 was
observed with cells transfected with WT GLI1, but not with cells
transfected with GLI13A mutant (Figures 3G and S3G). To identify
which AMPK phosphorylation site predominates, we repeated
the experiment of Figure 2B and co-transfected GLI1WT,
GLI13A, the three single mutants, and GLI1102A/1074A with
AMPK into HEK293 cells. In cells transfected with GLI13A, no
signal was detected with p-Sub/AMPK, and in cells containing
GLI1408A, the signal had 28% of the intensity compared
with GLI1WT (Figure 3H). GLI1102A and GLI11074A had 57% and
42% of the control signal, respectively, and the signal of the
102A/1074A double mutant was lower at 35% of the control
(Figure 3H).
To prove that AMPK can act directly upon GLI1, an in vitro
AMPK assay was performed. In Figure 3I, GLI13A was utterly
resistant to AMPK, which is similar to results shown in Figure 3H.
Each single mutation (102A, 408A, and 1074A) moderately
reduced the modiﬁcation by AMPK, from 20% to 60% (Figure 3I).
We conclude that S102, S408, and T1074 are all dominant AMPK
phosphorylation sites on GLI1.
GLI13A Has Higher Protein Stability and Transcriptional
Activity
Here we show that, compared to GLI1WT, the GLI13A mutant
protein has increased stability, is resistant to AMPK-mediated
suppression of Gli1 transcriptional activity, and stabilizes Gli1
mRNA at high levels. Using CHX to prevent new protein synthesis as in Figure 1, we found that, in transfected HEK293 cells,
GLI13A is considerably more stable than GLI1WT. We produced
a phospho-mimic version of GLI1 where each of the three
AMPK-phosphorylated residues was replaced by a glutamate;
this was called GLI13E and was highly unstable (Figure 4A, right).
Similarly, GLI13A was much more stable than GLI13E or GLI1WT
in NIH 3T3 cell lines in which GLI1 was stably produced
(Figure S4A).
To examine regulation of transcription by each version of GLI1,
we transfected genes encoding each of the forms into HEK293
cells. Each variant GLI1 was tested with or without co-transfected AMPK. Activation of transcription by GLI1 was measured
with a luciferase assay; the cells also were transfected with a
plasmid encoding eight Gli consensus sequences in cis to a luciferase gene (Sasaki et al., 1997). Transfected GLI1 activated this
target even without added Shh or other agonists. The samples
were normalized by comparison to cells transfected with vector
alone. Transcriptional induction by WT GLI1 was negatively
affected by adding AMPK, produced at two levels by transfecting 1 or 3 mg, even without adding 2DG (Figure 4B). In contrast,
GLI13A transcriptional activity was refractory to inhibition by
AMPK even at the higher level (Figure 4C). Further activation of
AMPK by added 2DG inhibited GLI1 target gene expression if
cells contained GLI1WT, but not if cells contained GLI13A (Figures
4D and 4E). We repeated the experiments using other AMPK
activators (AICAR and A79662) (Banko et al., 2011) in NIH 3T3
cell lines stably expressing GLI1 proteins. GLI13A had robust
resistance to 2DG-induced lowering of Gli1/Ptch1 mRNA levels
(Figures 4F and 4G). Each single mutant had a different degree
of moderate to great resistance to 2DG effects (Figures S4B
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Figure 3. AMPK Directly Phosphorylates GLI1
(A) HEK293 cells were co-transfected with Flag-tagged GLI1 or Flag-tagged FOXO3, with HA-tagged WT or AS-AMPKa2, and with AMPKb1 and g1. AS-AMPKa2
phosphorylates the known AMPK substrate FOXO3, which was detected using thioP antibody. FOXO3 and GLI1 were immunoprecipitated with antibodies that
recognize the Flag tag and blotted with thioP, Flag, or HA (AMPK) antibody. *Non-speciﬁc bands that were recognized by HA antibody.
(B) HEK293 cells were co-transfected with Flag-tagged GLI1 and HA-tagged AMPK, and cells were lysed in NP40 lysis buffer. GLI1 was immunoprecipitated
using an antibody to Flag and the precipitate was analyzed on a protein blot using AMPK phosphorylation-speciﬁc substrate antibody (p-Sub/AMPK) and Flag
antibody. The introduction of AMPK into the cells causes p-Sub/AMPK to label GLI1-Flag.
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and S4C). These results indicate that mutation of the three residues to alanine did indeed make GLI1 function refractory to inhibition by AMPK.
GLI13A Has Potent Cell Division-Stimulating and
Oncogenic Activity
To further investigate the function of these GLI1 mutants, we
generated stable cell lines in NIH 3T3 cells using lentiviral vectors
that produced GLI1WT, GLI13A, or GLI13E. The amount of GLI13A
protein that accumulated was about 1.4-fold that seen for
GLI1WT, normalizing both to actin (Figure 5A). Cell counting
with a hemacytometer showed that cells transduced with
GLI13A virus had a signiﬁcantly increased growth rate compared
to WT and GLI13E cell lines (Figure 5B). Colony formation assays
(Figure 5C) showed increased growth of GLI13A-bearing mutant
cells compared to other cell lines. To test the effect of activating
AMPK, 25 mM 2DG was added to the starting cultures and the
growth of colonies was measured 2 weeks later. An even higher
colony number difference was observed after treatment with
2DG (Figure 5D; Yang et al., 2008), but only for cells containing
GLI13A. Similar results were obtained using A769662 and AICAR
in the colony formation assay (Figure S5). To test the oncogenic
impact of GLI1WT in comparison to the mutant proteins, the
stably transfected cell lines producing the GLI1 variants were injected subcutaneously into nude mice. Tumor growth was monitored for 3 weeks. Cells that contained GLI13A grew to a volume
about 2.5 times that of the other three cell lines (Figure 5E).
DISCUSSION
The Hh pathway controls cell differentiation and growth in developing embryos and regenerating adult tissues. Most features of
the pathway components and their interactions are evolutionarily
conserved across many species from Drosophila to humans, in
developing and adult animals experiencing deprivation and
stresses, as well as circadian and annual rhythms that demand
adaptation of developmental mechanisms to circumstances.
One way that this happens is that the pathway itself has built-

in feedback controls that buffer the signaling. For example,
induction of the Gli1 gene by the pathway creates a positive
feedback loop that can maintain expression of target genes
including Gli1 itself. A restraining effect is mediated by the induction of ptch by the pathway, since the Ptch protein is a negative regulator. The amount of Ptch increases in response to
increased Hh ligand, so the pathway is buffered. Too much
ligand may be reined in by extra Ptch antagonist.
While these sorts of feedback controls are important, they do
not cope with the need to coordinate with all relevant aspects of
physiology. In particular, dramatic changes in energy stores
occur due to the changing abundance of food. Elaborate mechanisms have evolved for cells to adapt to high or low levels of
ATP (Hardie et al., 2012; Inoki et al., 2012). In some tissues,
such as ﬂy wing discs and mammalian cerebellum, Hh signaling
has powerful growth effects. Embarking on that growth when
ATP is scarce is unlikely to succeed and may lead to fatal imbalances among tissues and cell types. Thus, activation of AMPK in
response to high AMP levels shuts down central processes, such
as protein synthesis and ion transport (Lang and Föller, 2014),
while boosting other processes that increase hardiness and
allow survival until ATP stores are rebuilt. AMPK has many target
proteins that, together, allow coordinated shutdown of energydemanding activities (Hardie et al., 2012). Its activity can be triggered by stimuli such as exercise (Jessen et al., 2014), cytokines,
and hypoxia (Evans et al., 2012). Targets have been identiﬁed in
several ways, such as whole-cell proteomics (Banko et al., 2011),
in vitro tests (Gwinn et al., 2008), and genetics (Mihaylova and
Shaw, 2011). The full range of targets is not known, but among
them are transcription factors such as E2F1 (Yang et al., 2014),
Msn2 (Petrenko et al., 2013), and FoxO3a (Greer et al., 2007).
A recent paper showed that AMPK negatively regulates Gli1 in
hepatocellular carcinoma (HCC), but did not address the mechanism (Abi et al., 2011; Xu et al., 2014). They showed that expression of AMPK is negatively correlated with Gli1 in HCC. Their
work provides a useful example of the effect of reduced AMPK
function in a tumor; as in our experiments, tumor growth is stimulated when Gli1 is not targeted by AMPK.

(C) AMPK+/+ and AMPK / MEFs were virus infected with Flag-tagged GLI1 and treated with 25 mM 2DG and 0.75 mM AICAR for 30 min, and cells were lysed in
NP40 lysis buffer. The cells lysates were analyzed as shown as (B).
(D) HEK293 cells were co-transfected with Flag-tagged GLI1 and AMPKa2, b1, and g1. Cells were lysed in NP40 lysis buffer. The lysates were subjected to
immunoprecipitation using an antibody to Flag-tag, and the GLI1 band was isolated and subjected to mass spectrometry. Extracted ion chromatograms (EICs)
identiﬁed phosphorylated peptides S102, S408, and T1074. The insets represent the fragment ion spectra determined using high-energy dissociation (HCD).
(E) Alignment of two conserved sites (S102 and T1074) in GLI1 that match the optimal AMPK substrate motif and are conserved from human to zebraﬁsh. S408 is
present only in the human sequence.
(F) HEK293 cells were co-transfected with Flag-tagged GLI1WT or Flag-tagged GLI13A, either WT-AMPKa2 or AS-AMPKa2, and AMPK b1 and g1. Cells were
lysed in NP40 lysis buffer. Substrates were immunoprecipitated with antibodies to Flag-M2 and blotted with thioP or Flag antibody.
(G) 2DG-stimulated phosphorylation of GLI1. (Left) HEK293 cells were transfected with Flag-tagged GLI1WT or GLI13A; 36 hr after transfection, they were treated
with 25 mM 2DG for 30 min, long enough to activate AMPK but not long enough to cause breakdown of Gli1. The lysates were subjected to immunoprecipitation
using an antibody to Flag-tag and immunoblotted with phospho-GLI11074 and Flag antibodies. The strong labeling in the center top lane shows that WT GLI1, but
not GLI13A, is phosphorylated by AMPK. (Right) Lysates prepared as at left were immunoblotted with antibodies against Flag, phospho-AMPK (p-AMPK),
phospho-ACC (p-ACC), and b-actin. The p-AMPK and p-ACC lanes show that the AMPK is stimulated by the 2DG. The actin lane controls for loading. The GLI1Flag lane shows stabilization of GLI1wt and of GLI13A in response to 2DG, though the response to 2DG disappears by 30 min.
(H) HEK293 cells were transfected with AMPK and Flag-tagged GLI1WT, GLI1102A, GLI1408A, GLI11074A, GLI1102A/1074A, and GLI13A. Gli1 was immunoprecipitated
using an antibody to Flag and the precipitate was analyzed on a protein blot using AMPK phosphorylation-speciﬁc substrate antibody (p-Sub/AMPK) and Flag
antibody. The introduction of AMPK into the cells causes p-Sub/AMPK to label GLI1-Flag. The number indicates the relative intensity of p-Sub/AMPK antibody.
(I) HEK293 cells were transfected with Flag-tagged GLI1WT, GLI1102A, GLI1408A, GLI11074A, and GLI13A. Cells were lysed in NP40 lysis buffer. Cell lysates were
immunoprecipitated with antibodies to Flag-M2 and the immunoprecipitated GLI1 proteins were subjected to in vitro AMPK assay. The number indicates the
relative intensity of AMPK activity.
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The GLI13A mutant has increased stability and is
resistant to AMPK-mediated suppression of Gli1
transcriptional activity.
(A) Lysates of HEK293 cells transfected with
Flag-GLI1WT, Flag-GLI13A, or Flag-GLI13E were
harvested at different times after treatment with
CHX (1 mg ml 1) and analyzed by immunoblot.
GLI13E has the two serines and one threonine that
are normally phosphorylated by AMPK changed
into glutamates to mimic phosphorylated GLI1.
(B) HEK293 cells were co-transfected with Gli1luciferase reporter, Gli1WT, and AMPK for 36 hr.
The two amounts of AMPK-expressing plasmid
used were 1 and 3 mg. Cell lysates were analyzed
using a luciferase assay to measure GLI1 transcriptional induction of the introduced Gli1-luciferase target gene. Representative results from
three experiments (n = 3), each conducted in
duplicate, are shown with SDs.
(C) HEK293 cells were co-transfected with
Gli1-luciferase reporter, GLI13A, and AMPK and
analyzed as in (B).
(D and E) NIH 3T3 cells were transfected with
vector control, GLI1WT, or GLI13A for 36 hr, then
treated with 2DG (25 mM) for 4 hr. RT-PCR was
used to measure (D) Gli1 mRNA and (E) Ptch1
mRNA. The experiment was repeated three times
(**p < 0.01, ***p < 0.001).
(F and G) NIH 3T3 vector, GLI1WT, and GLI13A
producing stable cell lines were treated with AICAR
(0.75 mM) and A769662 (150 mM) for 4 hr. RT-PCR
was used to measure (F) Gli1 mRNA and (G) Ptch1
mRNA. The experiment was repeated three times.
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proteins by other signaling pathways
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contributes to the formation of many
cancers with elevated Gli activity (Amakye et al., 2013; Hui and Angers, 2011;
3A
Niewiadomski et al., 2014). The mTOR/
S6K kinase pathway was shown to
enhance Gli1 transcriptional activity
(Wang et al., 2012). Since the mTOR/S6K pathway has been
reported to be involved in the development of various tumors,
targeting mTOR is becoming one of the major methods for
cancer treatment. In addition, AMPK has been shown to suppress mTOR/S6K1 activity through direct phosphorylation of
mTOR and Tuberous Sclerosis Complex (Kim et al., 2008),
the upstream negative regulator of mTOR (Kahn et al., 2005).
Given our ﬁndings, we now know that AMPK both directly
and indirectly suppresses the Hh/Gli1 pathway. AMPK conditional knockout models have been created (Viollet et al., 2009),
but the role of AMPK in tumorigenesis has not been extensively studied. Loss of AMPK is insufﬁcient to provoke tumor
formation in mice, but genetic ablation of the a1 catalytic subunit of AMPK accelerates the development of lymphomas
driven by Myc overexpression (Faubert et al., 2013). In
contrast, deletion of the AMPKa2, but not the AMPKa1, subunit of AMPK increases susceptibility to H-RasV12-induced
" A769662
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Our research shows that GLI1 can be added to the list of direct
AMPK targets. S408 is found in a sequence that perfectly
matches the AMPK consensus site, while S102 and T1074 (SP
and TP) sequences are not perfectly matched to the traditional
AMPK consensus site. We examined other kinases such as
p38 and JNK, MAPK-type proline-directed kinases, and found
that their inhibition did not inﬂuence Gli1 protein levels (data
not shown). Mutation of each of the individual sites on Gli1 impacts AMPK-mediated phosphorylation activity, and each mutation site may exert effects on other sites (Figures 3H and S3G).
Overall, current results show that two sets of AMPK-dependent
phosphorylation sites include two SP/TP sites (S102 and T1074,
Figures S3E and S3F), with high basal stoichiometry and modest
inducibility, and one site matching the AMPK consensus (S408,
Figures S3E and S3F), with low basal stoichiometry but very
high inducibility. Collectively, these AMPK-regulated sites in
GLI1 control its protein stability.
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(A) NIH 3T3 cells were infected with vector,
GLI1WT, GLI13A, or GLI13E lentivirus, with Flag tags
on each protein, and selected for 7 days with
puromycin (2.5 mg/ml 1). Cell lysates were
analyzed by immunoblotting with Flag antibody to
measure the amounts of the expressed proteins.
(B) This experiment used NIH 3T3 GLI1-stable cell
lines (vector control, WT, 3A, and 3E). 5 3 103 cells
were seeded into 12-well plates for growth assays,
each cell type in triplicate, and cells were counted
using a hemocytometer for 3 consecutive days.
The experiment was repeated three times (*p <
0.01, **p < 0.001).
(C) NIH 3T3 cells with GLI1WT, GLI13A, or GLI13E
stably expressed were seeded into six-well plates
for colony formation assays for 2 weeks. Colonies
larger than 1.5 mm were counted.
(D) As in (C), the cells were treated with 2DG (25 mM)
and 2DG-containing medium. The medium in 2DGtreated wells was changed every 3 days to refresh
the 2DG. Colony numbers were counted 2 weeks
later. In (C) and (D), each cell line was seeded in
duplicate, with n = 3 (*p < 0.05, ***p < 0.0001).
(E) NIH 3T3 GLI1-stable cell lines (vector control,
WT, 3A, and 3E). 107 cells were injected subcutaneously into the nude mice and tumor growth
was monitored for 3 weeks (**p < 0.001).
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EXPERIMENTAL PROCEDURES
All human subjects and animal manipulation protocol were under regulations of institutional review
board (IRB 1203012078) and Purdue Animal
Care and Use Committee (PACUC 1301000800),
respectively.

(Day)

transformation in murine ﬁbroblasts (Phoenix et al., 2012),
raising the interesting possibility that the AMPKa2 subunit
may contribute to tumor suppression in a way that is independent of, or in addition to, the energy-sensing function of
AMPK. This suggests that AMPK activity opposes tumorigenesis. Loss of AMPK function evidently fosters tumor progression, perhaps by heightening activities of pathways that spur
cell growth and proliferation.
In summary, we found that AMPK inhibits Gli1 protein
levels and transcriptional activity. AMPK phosphorylated
GLI1 at three novel sites and induced GLI1 protein degradation. Mutation of these three sites into alanine prolonged
GLI1 protein stability, transcriptional activity, and oncogenic
function (Figure 6). We report here that an energy sensor,
AMPK, directly targets the Hh transcriptional activator, GLI1,
and suppresses GLI1 activity. Revealing the detailed molecular mechanism of how AMPK modulates the Hh pathway will
enable us to further understand the coordination between
energy metabolism regulation and the Hh pathway during
development.

Reagents and Plasmids
AMPK activators 2DG and metformin were purchased from Sigma, AICAR was from Calbiochem,
and A-769662 was from Selleckchem. CHX and glucose were purchased from
Sigma. The dual-luciferase assay kit was purchased from Promega. The Gli1luciferase reporter contained eight directly repeated copies of the consensus
Gli1-binding site (Sasaki et al., 1997). GLI1 HA-tagged, Flag-tagged, and
pCDH-CMV-MCS-EF1-Puro constructs were gifts from Dr. Mien-Chie Hung
(Wang et al., 2012) (University of Texas MD Anderson Cancer Center). LKB1
shRNA plasmids were gifts from Dr. Hui-Kuan Lin (University of Texas MD Anderson Cancer Center). Mutated constructs derived from the control
HA-tagged and Flag-tagged GLI13A and GLI13E were generated using the
Quick Change multisite-directed mutagenesis kit from Stratagene. NheI-forward primer (50 GGCGAGCTAGCATGGACTACAAAGACCATGAC 30 ) and
BstBI-reverse primer (50 AGTATTCGACACCCCGGATCCTC 30 ) were used to
subclone the GLI1WT, GLI13A, and GLI13E into pCDH-CMV-MCS-EF1-Puro.
Immunoblotting and Immunoprecipitation Assays
Immunoblotting and immunoprecipitation were performed as previously
described (Yang et al., 2008), with the following antibodies: Gli1 and GFP
(Santa Cruz Biotechnology); Gli1, AMPK, p-AMPK, ACC, p-ACC, p-AMPK/
Sub, LKB1, JNK, p-JNK, p-38, and p-p38 (Cell Signaling Technology); Actin,
Tubulin, Flag-M2 (Sigma), and HA (Roche); and Thiophosphate Ester Speciﬁc
Ab (Epitomics). The Gli1 antibody used to generate the data shown was of the
Santa Cruz Biotechnology and Cell Signaling Technology antibodies at 1:1,000
dilution in 3% milk.
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Figure 6. AMPK Phosphorylates GLI1 and Inhibits Hedgehog
Pathway
The diagram shows that activated AMPK directly phosphorylates GLI1 on
S102, S408, and T1074 sites. Phosphorylation lowers GLI1 protein stability,
thus reducing GLI1 transcriptional activity, and mitigates cell growth.
Real-Time qPCR
Total RNA was isolated from NIH 3T3 ﬁbroblasts and PZp53MED cells using
Trizol reagent (Invitrogen). RNA (1 mg) was reverse-transcribed with random
hexamer primers using SuperScript III reverse transcriptase (Invitrogen). A
fraction (1/20) of the resultant cDNA was used as a template for ampliﬁcation
with TaqMan qPCR probes (Applied Biosystems) on an Applied Biosystems
7500 Fast thermocycler as follows: Gapdh (Mm99999915_g1), Gli1
(Mm00494645_m1), and Ptc1 (Mm00436026_m1).
Cell Culture, MTT Cell Growth, and Colony Formation Assay Analysis
NIH 3T3 cells were cultured in DMEM supplemented with 10% bovine calf
serum (BCS) at 5% CO2. All other cell cultures were kept in DMEM supplemented with 10% fetal bovine serum (FBS) at 5% CO2. The concentrations
and time for each chemical treatment were as follows: 2DG (25 mM, 4 hr)
and CHX (1 mg ml 1), unless otherwise noted. The cell growth rate was determined using MTT and cell-counting assays (Yang et al., 2008). For colony
formation assays, 5 3 104 cells were placed in 1.5 ml DMEM with 10% FBS
and 0.3% agarose and overlaid onto 3 ml DMEM with 10% FBS and 0.6%
agarose in each well of a six-well plate; medium with or without 25 mM 2DG
was applied to each well until the end of the assay. After 2–3 weeks, colonies
larger than 2 mm in diameter were counted.
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